obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials

Published 4 months ago • 178 plays • Length 2:00

Download video MP4
Download video MP3

Similar videos

1:36

cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
1:50

insights into the majic study: acalabrutinib venetoclax vs venetoclax obinutuzumab in cll
1:52

evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
1:00

reveng: venetoclax and obinutuzumab in cll
1:46

novel agent combinations for cll: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
1:36

obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in cll
2:45

optimizing the combination of ibrutinib plus venetoclax in cll
1:43

results from a phase ii trial of pirtobrutinib, venetoclax, and obinutuzumab in cll
12:05

venetoclax combinations, safety and efficacy
35:47

zanubrutinib for the treatment of waldenstrom's macroglobulinemia
7:27

acalabrutinib vs ibrutinib for previously treated cll
4:44

7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
2:36

obinutuzumab /- bendamustine debulking prior to venetoclax in cll
1:43

six-year update from cll14: fixed-duration venetoclax obinutuzumab for previously untreated cll
2:43

four-year follow-up from a phase ii study of obinutuzumab, ibrutinib, and venetoclax in cll
6:34

3-year follow-up of obinutuzumab, ibrutinib and venetoclax for cll
2:38

the boven trial: mrd-guided obinutuzumab, zanubrutinib and venetoclax regimen in tp53-mutated mcl
1:03

maic of zanubrutinib and venetoclax ibrutinib in treatment-naïve cll
1:56

emerging ibrutinib-based combinations in cll
5:34

venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
0:49

overview of the cll2-big trial of ibrutinib and obinutuzumab
1:05

final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll

Clip.africa.com - Privacy-policy